Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation

Inclusion Criteria: * Male or female patients 18 years of age or older * Patients deemed eligible to undergo autologous bone marrow or peripheral stem cell transplant therapy per usual transplant inclusion and exclusion criteria * Patients with Non-Hodgkins Lymphoma, Hodgkins Lymphoma or Multiple Myeloma or Amyloidosis * Written informed consent Exclusion Criteria: * Nausea at baseline * Chronic use of other antiemetic agent(s) * Gastrointestinal obstruction or active peptic ulcer * Radiation therapy to pelvis or abdomen within 1 week before or after study day 1 * Allogeneic stem cell transplant recipient * Aspartate transaminase (AST) \> 3x upper limit of normal (ULN) * Alanine transaminase (ALT) \> 3x ULN * Bilirubin \> 3x ULN * Alkaline phosphatase \> 3x ULN * Creatinine \> 2 * Documented hypersensitivity to any component of study regimen * Pregnant or lactating women * Participating in a clinical trial which involves other investigational agent(s) * Patients taking any of the following medications at time of study day 1: warfarin, oral contraceptives (except for the administration of stopping menses), tolbutamide, phenytoin, midazolam, ketoconazole, rifampin, paroxetine, and/or diltiazem.